SysMedPD

PD is the second most common neurodegenerative disease. Although both genetic and environmental factors have been shown to contribute to the development of Parkinson’s disease, the exact cause of the disease in individual patients is often still difficult to determine. In a subgroup of Parkinson’s disease patients however, mutations in single mitochondrial genes and/or mitochondrial dysfunction has been detected.

The SysMedPD project unites a highly experienced multidisciplinary consortium to improve understanding and detection of Parkinson's disease with mitochondrial dysfunction. Eight partners from five European countries will collaborate to discover and develop novel drug candidates, specifically tailored to patients suffering from Parkinson’s disease with overt mitochondrial dysfunction.